Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1996 1
1997 1
1999 1
2001 1
2005 1
2006 1
2007 7
2008 1
2009 1
2010 1
2011 1
2013 2
2014 5
2015 6
2016 7
2017 10
2018 10
2019 7
2020 24
2021 27
2022 20
2023 6
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Non-pharmacological Interventions for Intractable Epilepsy.
Alqahtani F, Imran I, Pervaiz H, Ashraf W, Perveen N, Rasool MF, Alasmari AF, Alharbi M, Samad N, Alqarni SA, Al-Rejaie SS, Alanazi MM. Alqahtani F, et al. Among authors: samad n. Saudi Pharm J. 2020 Aug;28(8):951-962. doi: 10.1016/j.jsps.2020.06.016. Epub 2020 Jun 29. Saudi Pharm J. 2020. PMID: 32792840 Free PMC article. Review.
Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V, Aw A, Laferriere N, Abdel-Samad N, Peters A, Johnson NA, Bernard MP, Gopalakrishnan S, Bull SJ, Fournier PA, Klil-Drori AJ, Hay AE, Robinson S, Owen C. Banerji V, et al. Among authors: abdel samad n. Leuk Lymphoma. 2024 May;65(5):609-617. doi: 10.1080/10428194.2024.2301738. Epub 2024 Jan 18. Leuk Lymphoma. 2024. PMID: 38235709
Utility of mTOR inhibition in hematologic malignancies.
Younes A, Samad N. Younes A, et al. Among authors: samad n. Oncologist. 2011;16(6):730-41. doi: 10.1634/theoncologist.2010-0318. Epub 2011 May 31. Oncologist. 2011. PMID: 21632450 Free PMC article. Review.
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Smith MR, Jegede OA, Martin P, Till BG, Parekh SS, Yang DT, Hsi ED, Witzig T, Dave S, Scott D, Hanson C, Kostakoglu Shields L, Abdel-Samad N, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum KA, Romer MD, Inwards DJ, Lerner RE, Wagner LI, Little RF, Friedberg JW, Leonard JP, Kahl BS. Smith MR, et al. Among authors: abdel samad n. Blood. 2024 Sep 5;144(10):1083-1092. doi: 10.1182/blood.2024023962. Blood. 2024. PMID: 38820500 Clinical Trial.
140 results